Viquglip-D
Description_Effects
Viquglip-D is a dual-action oral antidiabetic medication that combines Dapagliflozin and Vildagliptin to help manage type 2 diabetes mellitus effectively. This unique combination targets both insulin regulation and glucose elimination, offering improved glycemic control. Dapagliflozin is an SGLT2 inhibitor that works by increasing glucose excretion through urine, thereby lowering blood sugar levels naturally and independently of insulin. It also contributes to modest weight loss and blood pressure reduction, providing added benefits in patients with type 2 diabetes and associated cardiovascular risks. Vildagliptin, a DPP-4 inhibitor, enhances the action of incretin hormones. It helps the pancreas release more insulin after meals and reduces glucagon secretion, leading to decreased hepatic glucose production. This dual mechanism helps maintain stable blood sugar levels throughout the day, especially after food intake. Together, these two agents complement each other by addressing different mechanisms in diabetes management—offering better glucose control while minimizing the risk of hypoglycemia. Viquglip-D should be taken as prescribed by your doctor, along with proper diet, exercise, and lifestyle modifications. Regular use can significantly improve blood sugar control and help reduce the risk of long-term diabetes-related complications.
